OMRON Healthcare announces NightView – the world’s first wrist automatic nocturnal Home Blood Pressure Monitor

Up to 1 in 4 people with normal daytime blood pressure may have nocturnal hypertension.
Sleeping blood pressure (BP) measurements are stronger indicators of heart health than daytime values.
NightView provides convenient, clinically validated BP readings while asleep from home.

Brussels, Belgium, 8 March, 2021 - OMRON Healthcare, a global leader in health monitoring and therapy, today announces NightView, the world’s first* wrist home use automatic blood pressure monitor (HBPM) designed for night-time, sleep-based and daytime readings with clinically validated accuracy.

Up to 1 in 4 patients1 with normal daytime blood pressure (BP) may have high-blood pressure (hypertension) at night, known as nocturnal hypertension. Further to this, night-time or sleeping BP readings are stronger predictors of cardiovascular (CV) events, including strokes and heart attacks and even death, than day-time values for hypertensive patients2. As such, accurate and readily accessible tracking of both day-time and night-time BP provides hypertensive patients and their clinicians with a much fuller picture of CV health, and helps reduce risk of CV events.

Conditions that are known to increase risk of nocturnal hypertension include2-3:

  • Sleep disturbance
  • Diabetes
  • Obstructive sleep apnea
  • Older age
  • Stress autonomic dystonia
  • Heart failure
  • Treatment-resistant hypertension
  • Kidney failure

In spite of its crucial importance to predict CV events, there were no home use wrist blood pressure monitors capable of measuring nocturnal blood pressure when the patient is asleep before the NightView. While ambulatory blood pressure monitoring (ABPM) continues to be the gold standard for measuring nocturnal BP, this technique is known to disrupt sleep4, which can result in BP values that might be different to the true value when the patient is asleep.

Designed specifically to provide patients and clinicians with total insight into their CV health, NightView is equipped with a comfortable wrist-cuff with completely silent pumping action along with gentle inflation and less compression time compared to ABPM. As a consumer friendly, yet clinically validated device sold for home use, NightView allows for regular nocturnal and daytime readings to be taken from the comfort of the patient’s home and with very limited impact on sleep quality. A luxury that the European Society of Cardiology guidelines said did not exist3, until now.

How it works:

  • NightView takes three readings per night at specific time points, to provide a more accurate assessment of nocturnal blood pressure values.
  • The unique wrist-cuff design ensures that measurements are accurate even if the wrist rotates at night.
  • The device also enables patients to record and sync their patient generated health data via the OMRON connect app, providing healthcare practitioners with advanced insights into their patient’s cardiovascular health.

“Without reliable access to nocturnal BP readings, healthcare professionals, in effect, only have half the picture,” said Lucía Prada, Marketing Director of OMRON Healthcare. “This technology will provide clinicians and patients alike with the clarity, certainty and comfort that their treatment programmes are fully optimised and informed. Nightview marks a significant step in our journey towards zero cardiovascular events. With this technology in our toolbox, we are now more than ever determined to make Going for Zero a reality.”

“Nightview’s development and validation, along with the proliferation of medical grade technology into the hands of the public, is helping overcome current challenges and limitations in the patient-health service relationship,” added Andre van Gils, President and CEO of OMRON Healthcare EMEA. “With empowered patients now able to provide reliable, clinically validated measurements from home with minimal sleep disturbance, healthcare professionals can be equipped with the tools and data they need to see a truer picture of a patient’s cardiovascular health.”

NightView builds on OMRON Healthcare’s years of technology innovation in providing medical grade, consumer friendly technology in the field of cardiovascular health.

NightView is available for purchase as part of OMRON Healthcare’s exclusive range of products.

About OMRON Healthcare

Committed to helping people live more active and fulfilling lives with zero compromise, OMRON Healthcare is a global leader in the field of clinically proven, innovative medical equipment for health monitoring and therapy.

Throughout its 87-year history OMRON Healthcare has been striving to improve lives and contribute to a better society by developing innovations that help people prevent, treat and manage their medical conditions, both at home and in clinical practice in over 117 countries.

OMRON Healthcare is the No. 1 brand recommended by cardiologists in Europe for blood pressure monitors and the Global No. 1 brand in nebulisers for respiratory treatment with over 30 million devices sold. The company’s additional core product categories are low-frequency pain therapy equipment, body composition monitors and electronic thermometers.

OMRON Healthcare Group is headquartered in Kyoto, Japan. OMRON Healthcare Europe B.V. is the healthcare division for Europe, Russia, Middle East and Africa and provides services to customers in more than 74 countries.

OMRON Healthcare Europe B.V.
Scorpius 33, 2132 LR Hoofddorp, The Netherlands
+31 (0)23 55 44 700,


* It should be noted that ABPM technology is not considered HBPM
1 Kario K, Hoshide S, Haimoto H, et al. Sleep blood pressure self-measured at home as a novel determinant of organ damage: Japan morning surge home blood pressure (J-HOP) study. J Clin Hypertens (Greenwich). 2015;17(5):340-348
2 HHS Public Access, Role of Ambulatory and Home Blood Pressure Monitoring in Clinical Practice: A Narrative Review
3 Cappuccio, F. The Role of Nocturnal Blood Pressure and Sleep Quality in Hypertension Management. European Cardiology Review. 2020;15(60).
4 2018 ESC/ESH Guidelines for the management of arterial hypertension